NorthWest Biotherapeutics Inc (NWBO)

[ou71764]

pgsd, thanks for pointing me to that post. It's definitely encouraging. For some patients in the trial, the therapy has no doubt been effective. If that's what LL meant, I agree.

Nonetheless, for whatever reason, there are always some patients in a trial who do better than expected. I don't accept the premise that a fat tail is all that matters. If mOS isn't stat sig, then an insurance company would be expected to cover the cost of both chemo and the additional 6 figure cost of DCVax-L, when the combined therapies didn't extend the life expectancy of the average patient.

I wouldn't gloss over this comment by LL, as if she doesn't really mean it: "we don’t know who’s who—that could be in issue in terms of FDA approval."